Published in J Virol on December 01, 2003
CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A (2004) 3.01
L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A (2004) 1.48
Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol (2004) 1.23
Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol (2004) 1.08
Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay. J Virol (2006) 0.97
Hepatitis C virus infection. N Engl J Med (2001) 18.67
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 7.53
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol (2002) 6.69
Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31
Replication of hepatitis C virus. J Gen Virol (2000) 6.08
Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol (2002) 5.21
Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol (1994) 4.21
A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol (1998) 3.13
Formation of native hepatitis C virus glycoprotein complexes. J Virol (1997) 2.87
Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol (1993) 2.58
Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology (1996) 2.44
Complex processing and protein:protein interactions in the E2:NS2 region of HCV. Virology (1994) 2.27
Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol (1999) 2.26
Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol (2001) 2.19
Protein localization and virus assembly at intracellular membranes. Curr Top Microbiol Immunol (1991) 2.18
Characterization of pseudotype VSV possessing HCV envelope proteins. Virology (2001) 2.15
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem (1998) 2.14
Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol (1998) 2.09
Characterization of truncated forms of hepatitis C virus glycoproteins. J Gen Virol (1997) 2.06
Vaccinia virus induces cellular mRNA degradation. J Virol (1983) 2.02
Characterization of early stages in vaccinia virus membrane biogenesis: implications of the 21-kilodalton protein and a newly identified 15-kilodalton envelope protein. J Virol (1997) 2.00
The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J Virol (1999) 1.97
Vaccinia virus infection disrupts microtubule organization and centrosome function. EMBO J (2000) 1.96
Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol (2002) 1.94
The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization. J Biol Chem (2000) 1.94
Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science (2000) 1.64
Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol (2002) 1.61
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins. EMBO J (2002) 1.52
Cell fusion activity of hepatitis C virus envelope proteins. J Virol (2000) 1.50
Semliki forest virus budding: assay, mechanisms, and cholesterol requirement. J Virol (2000) 1.27
Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J Gen Virol (1999) 1.23
Transfection of HepG2 cells with infectious hepatitis C virus genome. Am J Pathol (1997) 1.23
The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum. J Gen Virol (1999) 1.15
Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro. Hepatology (1997) 1.15
The transmembrane domain of the hepatitis C virus E2 glycoprotein is required for correct folding of the E1 glycoprotein and native complex formation. Virology (2001) 1.14
Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology (2000) 1.11
Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein. J Biol Chem (2000) 1.07
Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients. J Infect Dis (2002) 1.06
Covalent interactions are not required to permit or stabilize the non-covalent association of hepatitis C virus glycoproteins E1 and E2. J Gen Virol (1999) 1.01
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2. J Gen Virol (2001) 1.00
Hepatitis C virus structural proteins reside in the endoplasmic reticulum as well as in the intermediate compartment/cis-Golgi complex region of stably transfected cells. Virology (2001) 0.98
Analysis of the C-terminal membrane anchor domains of hepatitis C virus glycoproteins E1 and E2: toward a topological model. J Virol (2002) 0.91
Purification and characterization of a protein synthesis inhibitor associated with vaccinia virus. J Biol Chem (1986) 0.89
Adverse effects of MVA-T7 on the transport of Marburg virus glycoprotein. J Virol Methods (2001) 0.86
Ultrastructural observations of viral particles within hepatitis C virus-infected human B lymphoblastoid cell line. Res Virol (1997) 0.85
Post-translational folding of the influenza C virus glycoprotein HEF: defective processing in cells expressing the cloned gene. J Gen Virol (1994) 0.81
Expression of the hepatitis C virus structural proteins in mammalian cells induces morphology similar to that in natural infection. J Viral Hepat (2002) 0.79
Cre/loxP-based reversible immortalization of human hepatocytes. Cell Transplant (2001) 0.78
Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology (2008) 3.99
CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A (2004) 3.01
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol (2002) 2.90
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A (2003) 2.21
Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nat Biotechnol (2006) 2.21
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol (2008) 2.06
Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology (2006) 2.04
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71
Intramuscular transplantation of engineered hepatic tissue constructs corrects acute and chronic liver failure in mice. J Hepatol (2009) 1.64
The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol (2008) 1.63
A whole-organ regenerative medicine approach for liver replacement. Tissue Eng Part C Methods (2011) 1.60
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology (2006) 1.59
Resetting the transcription factor network reverses terminal chronic hepatic failure. J Clin Invest (2015) 1.58
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Protective role of R-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndrome in mice. PLoS One (2009) 1.55
Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci U S A (2006) 1.53
Hepatocyte transplantation. J Hepatol (2004) 1.50
Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics (2003) 1.49
Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation. Gastroenterology (2003) 1.48
L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A (2004) 1.48
Hepatic repopulation with stably transduced conditionally immortalized hepatocytes in the Gunn rat. J Hepatol (2008) 1.47
Parent perspectives on decisions to participate in a phase I hepatocyte transplant trial. Pediatr Transplant (2013) 1.46
Barriers to the successful treatment of liver disease by hepatocyte transplantation. J Hepatol (2010) 1.41
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine (2009) 1.37
Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol (2006) 1.35
Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol (2007) 1.34
Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell (2010) 1.32
Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant (2012) 1.31
An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology (2006) 1.29
Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. Hepatology (2009) 1.23
Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. Nat Protoc (2007) 1.22
Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. J Virol (2009) 1.19
Treatment of liver failure in rats with end-stage cirrhosis by transplantation of immortalized hepatocytes. Hepatology (2002) 1.18
Human hepatocyte transplantation. Methods Mol Biol (2010) 1.17
Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection. Hepatology (2002) 1.17
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res (2005) 1.14
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
Hepatocyte transplantation. Transplantation (2004) 1.09
The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. Hepatology (2012) 1.07
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol (2003) 1.06
CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates. J Virol (2002) 1.04
Review of hepatocyte transplantation. J Hepatobiliary Pancreat Surg (2008) 1.01
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res (2006) 0.99
Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology (2007) 0.98
Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1. Transplantation (2008) 0.98
Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia. Hum Mol Genet (2013) 0.98
Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1. J Virol (2005) 0.97
Spontaneous hepatic repopulation in transgenic mice expressing mutant human α1-antitrypsin by wild-type donor hepatocytes. J Clin Invest (2011) 0.96
Route of hepatocyte delivery affects hepatocyte engraftment in the spleen. Transplantation (2003) 0.94
A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res (2007) 0.93
New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants. Stem Cell Res (2013) 0.92
Noninvasive evaluation of liver repopulation by transplanted hepatocytes using 31P MRS imaging in mice. Hepatology (2006) 0.90
Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias. Am J Nephrol (2005) 0.90
Hepatic differentiation of mouse iPS cells in vitro. Cell Transplant (2010) 0.89
Ex vivo gene transfer into hepatocytes. Methods Mol Biol (2009) 0.89
Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. Diabetes (2007) 0.89
Role of cysteine residues in the function of human UDP glucuronosyltransferase isoform 1A1 (UGT1A1). Biochem J (2005) 0.88
Hepatocyte transplantation: state of the art and strategies for overcoming existing hurdles. Ann Hepatol (2004) 0.86
Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. PLoS One (2012) 0.86
Instant hepatic differentiation of human embryonic stem cells using activin A and a deleted variant of HGF. Cell Transplant (2006) 0.86
Cell culture and animal models of viral hepatitis. Part I: hepatitis B. Lab Anim (NY) (2004) 0.86
Hepatic differentiation of liver-derived progenitor cells and their characterization by microRNA analysis. Liver Transpl (2010) 0.84
To be or not to be: generation of hepatocytes from cells outside the liver. Gastroenterology (2008) 0.84
Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int (2007) 0.83
Differentiating stem cells into liver. Biotechnol Genet Eng Rev (2008) 0.83
All-human microphysical model of metastasis therapy. Stem Cell Res Ther (2013) 0.83
Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon. Hepatology (2009) 0.83
An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model. Radiat Res (2014) 0.83
Isolated liver transplantation in infants with end-stage liver disease associated with short bowel syndrome. Ann Surg (2002) 0.82
Omeprozole therapy in pediatric patients after liver and intestinal transplantation. J Pediatr Gastroenterol Nutr (2002) 0.81
Rapid and sensitive assessment of human hepatocyte functions. Cell Transplant (2014) 0.81
Hypothermic storage of human hepatocytes for transplantation. Cell Transplant (2014) 0.81
Modeling and therapy of human liver diseases using induced pluripotent stem cells: how far have we come? Hepatology (2011) 0.80
Radiolabeled constructs for evaluation of the asialoglycoprotein receptor status and hepatic functional reserves. Bioconjug Chem (2003) 0.80
Heart xenograft survival with chimeric pig donors and modest immune suppression. Ann Surg (2003) 0.79